One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Editorial introductions.
doi : 10.1097/BOR.0000000000000936
Volume 35(3) pgs. v-v,135-212 May 2023
Tocilizumab in giant cell arteritis: an update for the clinician.
Ford, Julia A. a; Gewurz, Danya b; Gewurz-Singer, Ora a
doi : 10.1097/BOR.0000000000000937
The recent approval of tocilizumab (TCZ) for the treatment of giant cell arteritis (GCA) has changed the landscape for management of this disease. Herein, we review recent literature addressing practical questions for the clinician regarding the use of TCZ in GCA.
Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe, Melissa; Bermas, Bonnie L.
doi : 10.1097/BOR.0000000000000935
Immune check point inhibitors (ICIs) are a unique class of cancer treatments that harness the body's innate antitumor response. Although these medications have transformed oncology care, they also lead to generalized immune activation that can result in toxicities across a spectrum of organ systems called immune-related adverse events.
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Ambati, Amala; Knight, Jason S.; Zuo, Yu
doi : 10.1097/BOR.0000000000000932
Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families.
Glucocorticoid-induced osteoporosis in premenopausal women: management for the rheumatologist.
Chakrabarti, Katherine; McCune, W. Joseph
doi : 10.1097/BOR.0000000000000934
This review seeks to summarize the literature relevant to the treatment of glucocorticoid-induced osteoporosis in premenopausal women; an issue commonly encountered by rheumatologists and yet lacking good clinical practice guidelines.
Fibromyalgia and centralized pain in the rheumatoid arthritis patient.
Minhas, Deeba a; Murphy, Anne a; Clauw, Daniel J. b
doi : 10.1097/BOR.0000000000000929
Individuals with rheumatoid arthritis (RA) have traditionally been characterized as having nociceptive pain, leading to the assumption that effective immunosuppression should be enough to provide effective pain management.
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic.
Zaccardelli, Alessandra a; Wallace, Zachary S. b,c,d; Sparks, Jeffrey A. d,e
doi : 10.1097/BOR.0000000000000930
To summarize the findings of studies investigating patients with rheumatoid arthritis (RA) and risk of acute and postacute COVID-19 outcomes 3 years into the pandemic.
How can ultrasonography help in the management of CPPD? From diagnosis to clinical subset identification.
Filippou, Georgios; Sirotti, Silvia
doi : 10.1097/BOR.0000000000000939
Clinical manifestations of calcium pyrophosphate deposition (CPPD) disease are quite heterogeneous, ranging from asymptomatic presentation to severe forms of arthritis.
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis.
Galli, Elena a; Pipitone, Nicolo b; Salvarani, Carlo a
doi : 10.1097/BOR.0000000000000931
The aim of this article was to review the recent contributions on the role of PET in assessing disease activity in patients with large-vessel vasculitis (giant cell arteritis and Takayasu arteritis).
Inflammatory eye disease for rheumatologists.
Corbitt, Kelly a; Nowatzky, Johannes a,b,c
doi : 10.1097/BOR.0000000000000933
This review provides a framework for understanding inflammatory eye disease diagnosis, differential diagnosis, and management for rheumatologists. Uveitis, scleritis, episcleritis, peripheral ulcerative keratitis, and orbital inflammation are all discussed.
